Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
These results are discussed in the light of previously published series and case reports of Whipple disease.
-
The accuracy of the clinical diagnosis of corticobasal degeneration (CBD) is unknown.
-
These findings indicate that immunostaining with these antibodies is essential for the evaluation of frontal dementia.
-
3D-SSP enables quantitative data extraction and reliable localization of metabolic abnormalities by means of stereotactic coordinates.
-
Because even the very mildly demented brains showed substantial pathological change, emphasis was placed on examining the nondemented cases for the earliest changes that could be associated with Alzheimer's disease.
-
The form and distribution of senile plaques (SP) and neurofibrillary tangles (NFT) has been examined in the brains of 13 patients with Down's syndrome (DS), aged less than or equal to 50 years, using immunocytochemical and silver staining procedures.
-
42/100
Tau aggregates accumulate in the Alzheimer's disease (AD) brain according to the established Braak staging scheme and spread from transentorhinal over limbic regions to the neocortex.
-
Three monoclonal antibodies directed against specific forms of the amyloid-β (Aβ) peptide have been granted accelerated or traditional approval by the FDA as treatments for Alzheimer disease, representing the first step towards bringing disease-modifying treatments for this disease into clinical practice.
-
With full FDA approval and Centers for Medicare & Medicaid Services coverage of lecanemab and donanemab, a growing number of practices are offering anti-amyloid immunotherapy to appropriate patients with cognitive impairment or mild dementia due to amyloid-positive Alzheimer disease.
-
Alzheimer's disease (AD), a primary cause of dementia globally, is traditionally diagnosed via cerebrospinal fluid (CSF) measures and positron emission tomography (PET).
-
By employing the hybridoma technique, 49 mAbs recognizing Tau (1-22), nine mAbs targeting p-Tau231, one mAb targeting p-Tau217, and two mAbs targeting p-Tau181 were developed.
-
With the advent of PET imaging in 1976, 2-deoxy-2-[18F]fluoro-D-glucose (FDG)-PET became the preferred method for in vivo investigation of cerebral processes, including regional hypometabolism in Alzheimer's disease.
-
High diagnostic sensitivity and negative predictive value (NPV) for Aβ-PET positivity were observed, consistent with the clinical performance of other plasma LC-MS/MS assays, but with greater separation between Aβ42/40 values for individuals with positive vs negative Aβ-PET results.
-
Patients with Alzheimer's disease (AD) can now be treated with monoclonal antibodies aiming at clearing amyloid plaques from the brain parenchyma.
-
The aim of the present study is the evaluation of established Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers in patients with idiopathic normal-pressure hydrocephalus (iNPH), both individually and as a total profile, and the investigation of their use as potential predictors of Tap-test responsiveness.
-
Retinal Optical Coherence Tomography (OCT) allows the non-invasive direct observation of the central nervous system, enabling the measurement and extraction of biomarkers from neural tissue that can be helpful in the assessment of ocular, systemic and Neurological Disorders (ND).
-
Alzheimer's disease (AD) is a devastating neurodegenerative disorder that affects millions of people worldwide.
-
The neurogranin concentration was higher in improved (68%) compared to unimproved patients (median 365 ng/L (IQR 186-544) vs 330 (205-456); p = 0.046).
-
Ophthalmic biomarkers have long played a critical role in diagnosing and managing ocular diseases.
-
41/100
Aging is associated with changes in sleep structure and cerebral deposition of amyloid beta and tau proteins.
-
The number of elderly dogs is increasing significantly worldwide, and many elderly dogs develop canine cognitive dysfunction syndrome (CCDS).
-
The enhanced ultra-low-dose τ images showed apparent noise reduction compared with the ultra-low-dose images.
-
TAR DNA-binding protein 43 (TDP43) is a focus of research in late-onset dementias.
-
41/100
Plasma glial fibrillary acidic protein significantly correlated with cognitive function tests, including all subdomains, with a notable increase in the PDD group compared with the HC and PDND groups, while plasma neurofilament light chain captured both cognitive decline and disease severity in the PDND and PDD groups.
-
Amyloid-beta (Aβ) is produced from amyloid precursor protein (APP) primarily after APP is internalised by endocytosis and clathrin-mediated endocytic processes are altered in Alzheimer's disease (AD).
From across this topic
10 of the 1,573 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Health-related factors and their impact on blood-based biomarkers of Alzheimer's disease
- Plasma Aβ42/40 predicts progression from Aβ-amyloid negative to positive PET scans
- Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivity
- Using cerebrospinal fluid biomarkers to diagnose Alzheimer's disease: an Australian perspective
- Unsupervised [18F]Flortaucipir cutoffs for tau positivity and staging in Alzheimer's disease
- Beyond Vision: A View from Eye to Alzheimer's Disease and Dementia
- Genetic and environmental contributions to variation in plasma phosphorylated tau 217
- Blood-based biomarkers for Alzheimer's disease
- Brain iron content in cerebral amyloid angiopathy using quantitative susceptibility mapping
- Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL® approaches: Validation against histopathology